Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celexa May Be Hidden Trophy In Warner-Lambert Bidding War

Executive Summary

Forest's antidepressant Celexa could either become the centerpiece of a newly created neuropharmaceutical marketing giant or an outlicensing candidate, depending on whether American Home Products or Pfizer prevails in its bid to acquire Warner-Lambert.

You may also be interested in...



Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger

Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.

Forest Reclaiming Celexa Ahead Of Warner-Lambert Merger

Forest is exercising its option to regain full marketing rights to the antidepressant Celexa (citalopram) under the change-in-control provisions of its co-promotion agreement with Warner-Lambert.

Warner-Lambert And AHP Plan Protonix Copromotion Agreement

Warner-Lambert and American Home Products intend to complete a co-promotion agreement for AHP's proton pump inhibitor Protonix.

Related Content

UsernamePublicRestriction

Register

PS035120

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel